Updated data request: Ovarian cancer risk factors by histologic subtypes and development of an ovarian cancer risk prediction model in the Ovarian Cancer Cohort Consortium (OC3)
I am resubmitting this request for two primary reasons 1) the co-PI, Dr. Shelley Tworoger has changed institutions, thus the data coordinating center is changing so we need to renew the data use agreement for the appropriate PI/institution, 2) we are requesting updated ovarian cancer outcomes (those available to extramural researchers since the original dataset creation) and updated information on exposures ascertained during follow-up (non-baseline questionnaire data), and information about biologic specimen availability. **It was suggested by Neal Freedman that we add Dr. Tworoger formally to this request so that the DTA can be taken care of via PLCO directly with Moffitt, rather than including as part of a combined DTA between NCI and Moffitt that also includes AARP and BCDDP.
Examining risk factors by tumor subtype. One broad research goal of the OC3 is to examine whether associations of putative ovarian cancer risk factors differ by ovarian cancer subtype. Thus far, we have defined subtypes by tumor histology/grade, dominance (as a surrogate for cell of origin), and aggressiveness (tumors fatal within three years vs. all others). Risk factors that have been analyzed include contraception history, reproductive history, postmenopausal hormone therapy, family history of ovarian cancer, anthropometric variables, analgesic use, and several biomarkers, including androgens, C-reactive protein, and insulin-like growth factors. We observed unique patterns of risk factor associations across subtypes. These results support that pre-diagnostic factors may influence ovarian cancer development and aggressiveness and that considering multiple tumor characteristics simultaneously may provide a clearer picture of disease etiology. Future research in the OC3 will continue to explore multi-faceted approaches to characterizing tumor heterogeneity (e.g., tumor immune marker profiles) and the associations of tumor subtypes with known and suspected risk factors.
Risk prediction. Although there are several known ovarian cancer risk factors, the ability to identify women at high risk remains limited. Thus, a major goal of the OC3 is to improve ovarian cancer risk prediction. On-going OC3 research is developing a risk prediction model for ovarian cancer overall. However, given the unique risk factor profiles of different ovarian cancer subtypes observed in previous OC3 research, and the poor performance of the model in predicting serous cancer (the most deadly subtype), the OC3 is focused on determining whether risk prediction models for ovarian cancer can be improved by accounting for differential associations by cancer phenotype. Research is currently underway to develop risk prediction models by tumor subtype.
Survival. Outside of surgery and chemotherapy, few factors have been associated with improved survival after diagnosis with ovarian cancer. An important goal of the OC3 is to conduct research to improve understanding of the impact of pre- and post-diagnosis exposures, and their interactions with tumor subtype, on survival. For example, we plan to characterize tumor immunosuppressive signatures related to poor prognosis, and examine their relationship with the trajectory of inflammation-related exposures before and after diagnosis. The long-term goal this research is to help focus efforts to develop novel cancer therapeutic strategies, and aid discovery of biomarkers for tailored treatment
Data repository expansion for future research aims. An important goal of the OC3 is to create an infrastructure with a core dataset of important variables for ovarian cancer epidemiology that will be available for future efforts to study ovarian cancer risk. Therefore, the OC3 plans to expand its data repository by obtaining funding to include dietary factors, updated exposure data from follow-up questionnaires, and biomarker information (both plasma/serum markers, including high-throughput omics data, and genetics, as available) that can be used to identify new risk factors as well as early detection markers.
Nicolas Wentzensen
Shelley Tworoger (Shelley.Tworoger@moffitt.org)
-
Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).
Townsend MK, Trabert B, Fortner RT, Arslan AA, Buring JE, Carter BD, Giles GG, Irvin SR, Jones ME, Kaaks R, Kirsh VA, Knutsen SF, Koh WP, Lacey JV, Langseth H, Larsson SC, Lee IM, Martínez ME, Merritt MA, Milne RL, ...show more O'Brien KM, Orlich MJ, Palmer JR, Patel AV, Peters U, Poynter JN, Robien K, Rohan TE, Rosenberg L, Sandin S, Sandler DP, Schouten LJ, Setiawan VW, Swerdlow AJ, Ursin G, van den Brandt PA, Visvanathan K, Weiderpass E, Wolk A, Yuan JM, Zeleniuch-Jacquotte A, Tworoger SS, Wentzensen N
Int J Epidemiol. 2021 Oct 15 PUBMED -
Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.
Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, Gaudet MM, Tjønneland A, Kvaskoff M, Kaaks R, Trichopolou A, Pala V, Onland-Moret NC, Gram IT, Amiano P, Idahl A, Allen NE, Weiderpass E, Poynter JN, Robien K, ...show more Giles GG, Milne RL, Setiawan VW, Merritt MA, van den Brandt PA, Zeleniuch-Jacquotte A, Arslan AA, O'Brien KM, Sandler DP, Wolk A, Håkansson N, Harris HR, Trabert B, Wentzensen N, Tworoger SS, Schouten LJ
Cancer Epidemiol Biomarkers Prev. 2020 Oct; Volume 29 (Issue 10): Pages 2010-2018 PUBMED -
Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.
Irvin S, Clarke MA, Trabert B, Wentzensen N
Cancer Causes Control. 2020 Oct; Volume 31 (Issue 10): Pages 869-879 PUBMED -
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).
Trabert B, Tworoger SS, O'Brien KM, Townsend MK, Fortner RT, Iversen ES, Hartge P, White E, Amiano P, Arslan AA, Bernstein L, Brinton LA, Buring JE, Dossus L, Fraser GE, Gaudet MM, Giles GG, Gram IT, Harris HR, Bolton JH, ...show more Idahl A, Jones ME, Kaaks R, Kirsh VA, Knutsen SF, Kvaskoff M, Lacey JV, Lee IM, Milne RL, Onland-Moret NC, Overvad K, Patel AV, Peters U, Poynter JN, Riboli E, Robien K, Rohan TE, Sandler DP, Schairer C, Schouten LJ, Setiawan VW, Swerdlow AJ, Travis RC, Trichopoulou A, van den Brandt PA, Visvanathan K, Wilkens LR, Wolk A, Zeleniuch-Jacquotte A, Wentzensen N, Ovarian Cancer Cohort Consortium (OC3)
Cancer Res. 2020 Mar 1; Volume 80 (Issue 5): Pages 1210-1218 PUBMED